We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$768M
AUM Growth
-$67.4M
Cap. Flow
-$112M
Cap. Flow %
-14.64%
Top 10 Hldgs %
90.53%
Holding
21
New
–
Increased
3
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$10.1M
2
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$5.42M
3
AKBA icon
Akebia Therapeutics
AKBA
+$1.13M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$49.7M
2
SPNC
Spectranetics Corp
SPNC
+$45.6M
3
OBSV
ObsEva SA Ordinary Shares
OBSV
+$23.2M
4
APEN
Apollo Endosurgery, Inc.
APEN
+$5.69M
5
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
+$3.27M

Sector Composition

Rank Sector Weight
1 Healthcare 92.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
1
Inogen
INGN
$167M
$338M 43.93%
3,549,320
– –
XLRN
2
DELISTED
Acceleron Pharma
XLRN
$58M 7.55%
1,553,937
– –
DERM
3
DELISTED
Dermira, Inc.
DERM
$51.9M 6.75%
1,921,580
+386,916
+25% +$10.1M
CRVS icon
4
Corvus Pharmaceuticals
CRVS
$1.1B
$51.7M 6.73%
3,244,046
– –
ANAB icon
5
AnaptysBio
ANAB
$1.6B
$41.6M 5.42%
1,190,604
-1,842,900
-61% -$49.7M
AKBA icon
6
Akebia Therapeutics
AKBA
$327M
$37.1M 4.83%
1,887,535
+73,246
+4% +$1.13M
FLXN
7
DELISTED
Flexion Therapeutics, Inc.
FLXN
$36.3M 4.72%
1,500,000
– –
RARX
8
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$29.7M 3.86%
2,031,562
– –
MRUS
9
DELISTED
Merus
MRUS
$28M 3.65%
1,410,417
– –
NBRV
10
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$23.8M 3.1%
11,615
+2,309
+25% +$5.42M
RETA
11
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$18.4M 2.4%
592,794
– –
KALV
12
DELISTED
KalVista Pharmaceuticals
KALV
$18.3M 2.39%
2,725,283
-176,644
-6% -$1.26M
IVTY
13
DELISTED
Invuity, Inc
IVTY
$12.1M 1.58%
1,363,848
– –
VRNA
14
DELISTED
Verona Pharma
VRNA
$11.4M 1.48%
740,740
– –
WMGIZ
15
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
0
– –
CRSP icon
16
CRISPR Therapeutics
CRSP
$4.58B
$3.99M 0.52%
223,317
– –
APEN
17
DELISTED
Apollo Endosurgery, Inc.
APEN
$1.28M 0.17%
274,472
-1,077,500
-80% -$5.69M
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.32B
– –
-127,563
Closed -$402K
OBSV
19
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-2,710,760
Closed -$23.2M
HTGM
20
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
– –
-6,836
Closed -$3.27M
SPNC
21
DELISTED
Spectranetics Corp
SPNC
– –
-1,187,917
Closed -$45.6M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q3 2017 Portfolio in Review

As of Q3 2017, Novo Holdings A/S held 21 positions worth $768M, down 8.1% from $836M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Novo Holdings A/S withdrew a net $112M in Q3 2017, closing 4 positions and reducing 3 holdings. Its most notable exit was Spectranetics Corp, an estimated $45.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier.

Against the trend, Novo Holdings A/S added an estimated $10.1M to Dermira, Inc..

  • Novo Holdings A/S added most to Dermira, Inc. in Q3 2017, an estimated $10.1M increase.
  • Novo Holdings A/S's biggest Q3 2017 reduction was AnaptysBio, cutting an estimated $49.7M.
  • Novo Holdings A/S fully exited Spectranetics Corp in Q3 2017, selling an estimated $45.6M.
  • Novo Holdings A/S's ten largest holdings make up 91% of its $768M portfolio in Q3 2017.
  • Novo Holdings A/S opened 0 new positions and closed 4 in Q3 2017.
  • Novo Holdings A/S's portfolio value fell 8.1% quarter-over-quarter to $768M.

Based on Novo Holdings A/S's 13F filing for Q3 2017, filed 14 Nov 2017.